Marc Bloomenstein, OD
Optometrist · Scottsdale, AZNPI 1568428910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $886,163 of the $1,365,153 with a category attached, or 64.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 20.7%. 2025 is the largest year on record at $294,465, 2.3 times the $130,159 reported in 2019. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,149 payments — averaging $635.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$283K
- Sun Pharmaceutical Industries Inc.$231K
- Bausch & Lomb Americas Inc.$202K
- Tarsus Pharmaceuticals, Inc.$153K
- Kala Pharmaceuticals, Inc.$115K
- Oyster Point Pharma, Inc.$80K
- plus $301K from 26 others
Across 65 payments — averaging $13,897 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$529K
- Oyster Point Pharma, Inc.$229K
- Tarsus Pharmaceuticals, Inc.$134K
- AbbVie$9K
- Shire North American Group Inc$3K
What the payments were for
- Consulting fees$303,44922%
- Speaking & faculty fees$886,16365%
- Travel & lodging$147,47311%
- Food & beverage$28,0692%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$226,041
- MIEBO$154,271
- XDEMVY$145,909
- XIIDRA$129,559
- VUITY$117,919
- EYSUVIS$115,399
- TYRVAYA$77,469
- RESTASIS MULTIDOSE$62,834
- TEARCARE SYSTEM$51,957
- Oxervate$46,896
- VYZULTA$38,585
- RESTASIS$36,182
- TRYPTYR$33,889
- One Series Ultra IOL Delivery System$22,887
- LUMIGAN$21,388
- TearCare SmartLid$20,532
- TEARCARE(TM) (2.2) SYSTEM KIT$20,532
- VEVYE$17,834
- COMBIGAN$13,734
- LOTEMAX SM$11,349
How this compares
$1,365,153 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 24 | $1,237,436 |
| XdemvyLotilaner | 93 | $175,522 |
| RestasisCyclosporine | 63 | $73,353 |
| MieboPerfluorohexyloctane/Pf | 52 | $39,551 |
| CequaCyclosporine | 33 | $26,788 |
| XiidraLifitegrast | 21 | $21,455 |
| Cyclosporine | 16 | $12,714 |
| LumiganBimatoprost | 26 | $8,922 |
| Prednisolone Acetate | 28 | $873 |
| Latanoprost | 63 | $381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $48,382 | $1,237,43624 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $153,316 | $175,52293 claims |
| AbbVieRestasis, Lumigan | $283,074 | $82,27689 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $202,461 | $61,00673 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $230,861 | $26,78833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Scottsdale
- Stephen CohenScottsdale$32K
- Andrew ZagelbaumScottsdale$25K
- Amanda GoldbergScottsdale$7K
- Daxa LadScottsdale$6K
- Tracy HutchingsScottsdale$6K
- Stephanie WooLake Havasu City$538K
- Jashpal RajasansiGilbert$104K
- Jamie KuhnGlendale$37K
- Tania SobchukLake Havasu City$32K
- Linda TrinhPeoria$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.